Live Breaking News & Updates on Phase 2 cerpass trial
Stay updated with breaking news from Phase 2 cerpass trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The combination of RP1 and cemiplimab provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, missing the primary end points of the phase 2 CERPASS trial.